Abstract
Abstract
Objective:
To describe the incidence of systemic overlap and typical coronavirus disease 2019 (COVID-19) symptoms in healthcare personnel (HCP) following COVID-19 vaccination and association of reported symptoms with diagnosis of severe acute respiratory coronavirus virus 2 (SARS-CoV-2) infection in the context of public health recommendations regarding work exclusion.
Design:
This prospective cohort study was conducted between December 16, 2020, and March 14, 2021, with HCP who had received at least 1 dose of either the Pfizer-BioNTech or Moderna COVID-19 vaccine.
Setting:
Large healthcare system in New England.
Interventions:
HCP were prompted to complete a symptom survey for 3 days after each vaccination. Reported symptoms generated automated guidance regarding symptom management, SARS-CoV-2 testing requirements, and work restrictions. Overlap symptoms (ie, fever, fatigue, myalgias, arthralgias, or headache) were categorized as either lower or higher severity. Typical COVID-19 symptoms included sore throat, cough, nasal congestion or rhinorrhea, shortness of breath, ageusia and anosmia.
Results:
Among 64,187 HCP, a postvaccination electronic survey had response rates of 83% after dose 1 and 77% after dose 2. Report of ≥3 lower-severity overlap symptoms, ≥1 higher-severity overlap symptoms, or at least 1 typical COVID-19 symptom after dose 1 was associated with increased likelihood of testing positive. HCP with prior COVID-19 infection were significantly more likely to report severe overlap symptoms after dose 1.
Conclusions:
Reported overlap symptoms were common; however, only report of ≥3 low-severity overlap symptoms, at least 1 higher-severity overlap symptom, or any typical COVID-19 symptom were associated with infection. Work-related restrictions for overlap symptoms should be reconsidered.
Publisher
Cambridge University Press (CUP)
Subject
Infectious Diseases,Microbiology (medical),Epidemiology
Reference31 articles.
1. 17. Local reactions, systemic reactions, adverse events, and serious adverse events: Moderna COVID-19 vaccine. Centers for Disease Control and Prevention website. https://www.cdc.gov/vaccines/covid-19/info-by-product/moderna/reactogenicity.html. Accessed April 19, 2021.
2. Research electronic data capture (REDCap)—A metadata-driven methodology and workflow process for providing translational research informatics support
3. Antibody Responses in Seropositive Persons after a Single Dose of SARS-CoV-2 mRNA Vaccine
4. 21. Moderna COVID-19 vaccine. Vaccines and Related Biological Products Advisory Committee December 17, 2020, meeting briefing document addendum- sponsor. Food and Drug Administration website. https://www.fda.gov/media/144453/. Published 2020. Accessed October 13, 2021.
5. 22. Moderna COVID-19 vaccine. Vaccines and Related Biological Products Advisory Committee December 17, 2020, meeting briefing document- sponsor, 2020. Food and Drug Administration website. https://www.fda.gov/media/144452/. Published 2020. Accessed October 13, 2021.
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献